Healthcare / Diagnostics & ResearchTaipei Exchange
$32.80
-0.05 (-0.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $7.2M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$708M
P/E
N/A
•EV/EBITDA
19.1x
↑ROE
-1.5%
↓Gross Margin
25.7%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.0%
FCF CAGR
—
FCF margin
1.9%
FCF / Net income
-0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $385.7M · net income $-9.4M · FCF $7.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $385.7M | $385.7M | $453.3M | $466.8M | $495.8M |
| Net Income | $-9.4M | $-9.4M | $18.4M | $11.5M | $42.8M |
| EBITDA | $34.1M | $34.1M | $66.3M | $51.5M | $91.6M |
| EPS | — | — | 0.85 | 0.54 | 2.00 |
| Gross Margin | 25.7% | 25.7% | 29.9% | 27.8% | 30.1% |
| Operating Margin | -8.7% | -8.7% | -0.7% | -3.4% | 0.7% |
| Net Margin | -2.4% | -2.4% | 4.1% | 2.5% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.06 | 0.06 | 0.08 | 0.10 | 0.12 |
| Current Ratio | 3.47 | 3.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $7.2M | $7.2M | $10.6M | $-859000.00 | $-18.6M |
| Returns | |||||
| ROE | -1.5% | -1.5% | 2.9% | 1.9% | 6.8% |
| Valuation | |||||
| P/E | — | — | 46.76 | 76.30 | 18.25 |
| EV/EBITDA | 19.13 | 19.13 | 12.08 | 16.44 | 8.02 |
| P/B | 1.13 | 1.13 | 1.34 | 1.42 | 1.24 |
| Growth & Yield | |||||
| Revenue Growth | -14.9% | -14.9% | -2.9% | -5.8% | — |
| EPS Growth | — | — | 57.4% | -73.0% | — |
| Dividend Yield | 0.9% | 0.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.85 → n/d
Residual
-0.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.